For decades, segments of the global pharmaceutical industry have approached Africa with hesitation. The dominant narrative has framed the continent as a “challenging frontier”—a region burdened by logistical constraints, uneven infrastructure, and opaque regulatory systems. While every geography presents complexities, this characterization of Africa is increasingly outdated. Over the last decade, data from multi-regional clinical trials have painted a very different picture: Africa is not merely a destination for philanthropic research, it is a high-performance region for global indications, offering competitive advantages in speed, cost efficiency, participant diversity and data quality.
Myth 1: African Regulatory Systems Are Slow and Unpredictable
The most persistent misconception is that African regulatory pathways are a “black box” beset by delays. While this may have reflected historical realities in certain countries, it no longer matches the current landscape. The establishment and maturation of the African Vaccine Regulatory Forum (AVAREF), now evolving into a broader platform supporting clinical trial excellence across Africa, has transformed the clinical research ecosystem (1). AVAREF’s coordinated joint review model enables simultaneous regulatory and ethics submissions across multiple countries, compressing joint scientific and ethics review timelines that previously stretched 6–18 months into approximately 10–15 days (2). These timeframes are not only competitive; they are increasingly competitive with timelines in some European and North American regions. For global sponsors, this means the regulatory pathway in Africa is no longer a gamble: it is predictable, harmonized, and increasingly aligned with international norms.
Myth 2: Recruitment in Africa Is Challenging
Another common misconception is that recruitment in Africa is slow, inefficient, or unreliable. The broader global picture shows that recruitment delays remain one of the largest drivers of drug development cost increases, less than half of clinical trials globally reach their target enrollment on time, often facing high dropout rates and prolonged timelines (3).
By contrast, recent evidence reveals that African trial sites routinely demonstrate strong recruitment and retention performance. A comprehensive review reported African site networks showing greater than 80% consent rates and retention between 85% and 96% indicating highly engaged participant populations and strong community involvement in trials (3). Several contextual factors contribute to this performance including large patient populations with limited prior exposure to clinical research for certain indications, particularly in areas with high disease burden and established community engagement networks that build trust and facilitate retention through the full study duration.
These advantages can translate into substantially shorter enrolment periods compared with many Western sites and reduce the risk of costly timelines slipping due to slow recruitment, which has historically been one of the largest causes of trial delays globally.
Myth 3: African Sites Lack Infrastructure for Complex Trials
A decade of sustained investment has rewritten this narrative. Funding from the European & Developing Countries Clinical Trials Partnership (EDCTP) (4), philanthropic organizations, and national health research programs has enabled the development of world class clinical research centers across the continent. These sites are equipped with modern laboratories and biobanking capacity, electronic data capture and real-time monitoring systems, skilled clinical, regulatory and quality-assurance staff, as well as proven adherence to Good Clinical Practice (GCP). These are not temporary or makeshift facilities; they are sophisticated research hubs whose data routinely feed FDA and EMA submissions. The perceived “quality gap” is a matter of outdated impressions, not performance.
What Sponsors Are Missing: The Real Risk Is Ignoring Africa
The perceived risk of operating in Africa is often amplified by unfamiliarity. Yet recent global-scale efforts, particularly the COVID-19 vaccine rollout, demonstrated the continent’s robust cold‑chain capacity and adaptable logistics networks—for example, during the distribution of COVID‑19 vaccines across multiple regions, and the agility of local implementing partners.
Meanwhile, excluding African populations from global research portfolios creates a critical data gap. With the continent representing the most genetically diverse region on earth, failing to generate data there weakens both clinical development programs and the generalizability of efficacy results. In today’s environment, the greater risk lies not in engaging in Africa, but in overlooking it.
Africa’s Value Proposition Is Already Proven
Africa’s competitiveness in clinical trials is ultimately a matter of data, not dogma. The evidence is clear. The regulatory pathways are fast, harmonized, and globally aligned. Recruitment is efficient, high-quality and reliable. Infrastructure meets, and in many cases exceeds, international sponsor and regulatory standards, and population diversity strengthens scientific rigor. Sponsors who continue to engage Africa solely through a humanitarian lens are missing a strategic commercial advantage. The continent is poised to shift from being a passive recipient of global health aid to becoming a core engine of global clinical development.
The question is no longer whether Africa is ready. It is whether the industry is ready to update its assumptions.
Reference List
- AVAREF [Internet]. [cited 2026 Feb 20]. Available from: https://avaref.afro.who.int/
- CEPI partners with AVAREF to boost clinical trial application reviews in Africa [Internet]. [cited 2026 Feb 20]. Available from: https://cepi.net/cepi-partners-avaref-boost-clinical-trial-application-reviews-africa
- Turner D de K Alan Boyce, and KarinKanewske. Controlled Clinical Trials in Sub-Saharan Africa: A Winning Value Proposition | Applied Clinical Trials Online [Internet]. 2026 [cited 2026 Feb 25]. Available from: https://www.appliedclinicaltrialsonline.com/view/controlled-clinical-trials-sub-saharan-africa-winning-value-proposition
- Driver S, Gray S,SikhondzeW, Awuonda K, Wilcox H, Segrt A, et al. The European & Developing Countries Clinical Trials Partnership (EDCTP) Knowledge Hub: developing an open platform for facilitating high-quality clinical research. Trials. 2022 May 7;23:374. doi:10.1186/s13063-022-06311-y PubMed PMID: 35526046; PubMed Central PMCID: PMC9077850.